Target type: biologicalprocess
The process of regulating the proliferation and elimination of myeloid cells such that the total number of myeloid cells within a whole or part of an organism is stable over time in the absence of an outside stimulus. [CL:0000763, GOC:add]
Myeloid cell homeostasis is a tightly regulated process that ensures a constant supply of mature myeloid cells, which include neutrophils, macrophages, monocytes, dendritic cells, and mast cells, to maintain immune function and tissue integrity. This intricate process involves a complex interplay of cellular and molecular factors that orchestrate the differentiation, proliferation, and survival of myeloid progenitors and their mature descendants.
**1. Myeloid Progenitor Differentiation:**
* **Pluripotent hematopoietic stem cells (HSCs)** reside in the bone marrow and possess the remarkable capacity to differentiate into all blood cell lineages, including myeloid cells.
* HSCs commit to **multipotent myeloid progenitors**, which can further differentiate into specific myeloid cell lineages.
* **Transcription factors** play a crucial role in directing lineage commitment. For example, PU.1 and C/EBPα are essential for myeloid lineage development.
**2. Myeloid Cell Proliferation and Maturation:**
* **Growth factors and cytokines** act as signaling molecules that stimulate the proliferation and differentiation of myeloid progenitors.
* **Granulocyte-macrophage colony-stimulating factor (GM-CSF)**, **macrophage colony-stimulating factor (M-CSF)**, and **granulocyte colony-stimulating factor (G-CSF)** promote the formation of specific myeloid cell lineages.
* **Signaling pathways** activated by growth factors and cytokines regulate gene expression and cellular processes involved in proliferation, differentiation, and survival.
**3. Myeloid Cell Survival and Apoptosis:**
* **Survival signals** from growth factors and cytokines help maintain the viability of myeloid cells.
* **Apoptosis**, or programmed cell death, eliminates unwanted or damaged cells, preventing the accumulation of abnormal cells.
* **Apoptosis regulators** such as Bcl-2 family proteins and caspases control the balance between survival and death.
**4. Myeloid Cell Migration and Function:**
* **Chemokines** act as chemoattractants, guiding mature myeloid cells to sites of inflammation or infection.
* **Adhesion molecules** on myeloid cells and endothelial cells facilitate the attachment and migration of cells across blood vessel walls.
* **Phagocytosis**, the engulfment and destruction of pathogens, is a key function of macrophages and neutrophils.
* **Antigen presentation**, the display of foreign antigens to T cells, is a crucial role of dendritic cells.
* **Mast cells** release histamine and other inflammatory mediators in response to allergens or pathogens.
**5. Regulation of Myeloid Cell Homeostasis:**
* **Feedback mechanisms** involving cytokines and growth factors help maintain a steady state of myeloid cell production.
* **Immune surveillance** mechanisms eliminate abnormal or cancerous myeloid cells.
* **Environmental factors** such as infection, inflammation, and stress can influence myeloid cell homeostasis.
**Dysregulation of Myeloid Cell Homeostasis:**
* Imbalances in myeloid cell homeostasis can lead to various diseases, including:
* **Leukemia**: Uncontrolled proliferation of myeloid cells.
* **Myelodysplastic syndromes**: Impaired myeloid cell maturation.
* **Autoimmune diseases**: Aberrant immune responses due to dysregulation of immune cells.
* **Infections**: Compromised immune function due to deficiencies in myeloid cells.
Myeloid cell homeostasis is a complex and dynamic process that plays a vital role in maintaining immune function and overall health. Understanding the intricate mechanisms involved is crucial for developing effective therapies for diseases associated with myeloid cell dysregulation.'"
Protein | Definition | Taxonomy |
---|---|---|
Nicastrin | A nicastrin that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q92542] | Homo sapiens (human) |
Bcl-2 homologous antagonist/killer | A Bcl-2 homologous antagonist/killer that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q16611] | Homo sapiens (human) |
Apoptosis regulator BAX | An apoptosis regulator BAX that is encoded in the genome of human. [PRO:SY, UniProtKB:Q07812] | Homo sapiens (human) |
Hepcidin | A hepcidin that is encoded in the genome of human. [PRO:DNx, UniProtKB:P81172] | Homo sapiens (human) |
Superoxide dismutase [Cu-Zn] | A superoxide dismutase [Cu-Zn] that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00441] | Homo sapiens (human) |
Bcl-2-like protein 11 | A Bcl-2-like protein 11 that is encoded in the genome of human. [PRO:WCB, UniProtKB:O43521] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
7-amino-4-chloro-3-methoxy-2-benzopyran-1-one | isocoumarins | ||
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
2-fluoroadenosine | adenosines; organofluorine compound | ||
tarenflurbil | tarenflurbil: R-enantiomer of flurbiprofen but not a COX inhibitor; modulates NF-kB, gamma-secretase, amyloid beta-protein; | flurbiprofen | |
cholanic acid | 5beta-cholanic acids; cholanic acid | ||
alexidine dihydrchloride | |||
formylmethionyl-leucyl-phenylalanine methyl ester | peptide | ||
6-n-tridecylsalicylic acid | 6-n-tridecylsalicylic acid: structure given in first source | hydroxybenzoic acid | |
anisomycin | (-)-anisomycin : An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin: An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. | monohydroxypyrrolidine; organonitrogen heterocyclic antibiotic | anticoronaviral agent; antimicrobial agent; antineoplastic agent; antiparasitic agent; bacterial metabolite; DNA synthesis inhibitor; protein synthesis inhibitor |
t0901317 | T0901317: an LXRalpha and LXRbeta agonist | ||
idarubicin hydrochloride | anthracycline | ||
4-chloro-1-methyl-3-nitro-2-quinolinone | nitro compound; quinolines | ||
1-methyl-4-[(4-methylphenyl)thio]-3-nitro-2-quinolinone | nitro compound; quinolines | ||
4-[[4-(2,5-dimethylphenyl)-1-piperazinyl]methyl]-2-methoxyphenol | piperazines | ||
2,5-dimethyl-1-(phenylmethyl)pyrrole-3,4-dicarboxaldehyde | arenecarbaldehyde | ||
N-(2,5-dimethylphenyl)-2-[[3-(4-ethylphenoxy)-4-oxo-1-benzopyran-7-yl]oxy]acetamide | chromones | ||
2-[(3-cyano-6-methyl-2-pyridinyl)thio]-N-(2-thiazolyl)acetamide | aromatic amide | ||
2-chloro-N-[3-[(2-chlorophenyl)methyl]-2-thiazolylidene]acetamide | organochlorine compound | ||
2-chloro-1-[1-[2-(4-chlorophenyl)ethyl]-2,5-dimethyl-3-pyrrolyl]ethanone | aromatic ketone | ||
2-[(3-methoxyphenyl)-oxomethyl]-3,3-bis(methylthio)-2-propenenitrile | carbonyl compound | ||
5-chloro-7-[3-pyridinyl-(2-pyridinylamino)methyl]-8-quinolinol | organochlorine compound; quinolines | ||
5-bromo-N-[2-(2-chlorophenyl)-1,3-benzoxazol-5-yl]-3-pyridinecarboxamide | 1,3-oxazoles | ||
5-chloro-7-[1-piperidinyl(2-pyridinyl)methyl]-8-quinolinol | organochlorine compound; quinolines | ||
1-(Chloroacetyl)-3-(1H-indol-3-yl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-4-ol | indoles | anticoronaviral agent | |
nsc 105827 | thiosangivamycin: structure given in first source | ||
2-[[2-[(2,5-dimethylphenyl)sulfonylamino]-1-oxoethyl]amino]-6-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide | amino acid amide | ||
2-chloro-N-(3-methyl-1,3-benzothiazol-2-ylidene)acetamide | benzothiazoles | ||
ML162 | ML162 : A monochlorobenzene that is benzene substituted by (chloroacetyl){2-oxo-2-[(2-phenylethyl)amino]-1-(thiophen-2-yl)ethyl}amino, chloro and methoxy groups at positions 1, 3 and 4, respectively. It is a covalent inhibitor of glutathione peroxidase 4 (GPX4) that induces ferroptosis in cells. | monochlorobenzenes; monomethoxybenzene; organochlorine compound; secondary carboxamide; tertiary carboxamide; thiophenes | EC 1.11.1.9 (glutathione peroxidase) inhibitor; ferroptosis inducer |
1-(Chloroacetyl)-5-[4-(difluoromethoxy)-3-methoxyphenyl]-3-thien-2-yl-4,5-dihydro-1H-pyrazole | methoxybenzenes | anticoronaviral agent | |
2-chloro-N-(2,6-dimethylphenyl)-3-oxo-3-phenylpropanamide | aromatic ketone | ||
5,6-dehydrokawain | 5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source | 2-pyranones; aromatic ether | |
n-oleoyldopamine | N-oleoyldopamine : A fatty amide resulting from the formal condensation of the carboxy group of oleic acid with the amino group of dopamine. Synthesised in catecholaminergic neurons, it crosses the blood-brain barrier and might be considered as a carrier of dopamine into the brain. It is a transient receptor potential vanilloid type 1 (TRPV1) receptor agonist. N-oleoyldopamine: putative capsaicin receptor ligand; produces hyperalgesia; isolated from the brain | catechols; fatty amide; N-(fatty acyl)-dopamine; secondary carboxamide | TRPV1 agonist |
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester | DAPT : A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor. | carboxylic ester; difluorobenzene; dipeptide; tert-butyl ester | EC 3.4.23.46 (memapsin 2) inhibitor |
sulindac sulfide | sulindac sulfide : An aryl sulfide that is a metabolite of sulindac. A non-steroidal anti-inflammatory drug, which also has anticancer activity. sulindac sulfide: sulfated analog of indomethacin & inhibitor of prostaglandin synthesis in vitro; RN given refers to cpd without isomeric designation; structure given in first source | aryl sulfide; monocarboxylic acid; organofluorine compound | antineoplastic agent; apoptosis inducer; non-steroidal anti-inflammatory drug |
l 685458 | L 685458: a gamma-secretase inhibitor; structure in first source L-685,458 : A peptide and carboxamide that is L-leucyl-L-phenylalaninamide, L-Leu-L-Phe-NH2, which has been acylated on the N-terminus by a Phe-Phe hydroxyethylene dipeptide isotere, 2R-benzyl-5S-tert-butoxycarbonylamino-4R-hydroxy-6-phenylhexanoic acid. Compounds based on the structure of L-685,458 are potent inhibitors of gamma-secretase, which mediates the final catalytic step that generates the amyloid beta-peptide (Abeta), which assembles into the neurotoxic aggregates in the brains of sufferers of Alzheimer's disease. | carbamate ester; monocarboxylic acid amide; peptide; secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor; peptidomimetic |
chaetoglobosin A | cytochalasan alkaloid; epoxide; indoles; macrocycle; secondary alpha-hydroxy ketone | Chaetomium metabolite | |
emetine hydrochloride | |||
mk 0752 | |||
ly 450139 | peptide | ||
chf 5074 | 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid: a beta-amyloid(1-42) lowering agent; structure in first source | ||
ly 411575 | dibenzoazepine; difluorobenzene; lactam; secondary alcohol | EC 3.4.23.46 (memapsin 2) inhibitor | |
abt-737 | aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound | anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor | |
4-(2-((1r)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid | sulfonamide | ||
begacestat | |||
e 2012 | |||
mrk 560 | MRK 560: a gamma-secretase inhibitor; MRK-560 is the (cis)-isomer; structure in first source | ||
5-chloro-2-[(4-methylphenyl)methylsulfonyl]-N-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-4-pyrimidinecarboxamide | pyrimidinecarboxamide | ||
5-chloro-2-[(3-methylphenyl)methylsulfonyl]-N-(5-propan-2-yl-1,3,4-thiadiazol-2-yl)-4-pyrimidinecarboxamide | pyrimidinecarboxamide | ||
5-chloro-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-(phenylmethyl)sulfonyl-4-pyrimidinecarboxamide | pyrimidinecarboxamide | ||
5-chloro-N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]-2-[(4-fluorophenyl)methylsulfonyl]-4-pyrimidinecarboxamide | pyrimidinecarboxamide | ||
amphidinolide b | amphidinolide B1: from Amphidinium sp.; structure in first source | ||
marinopyrrole a | (-)-marinopyrrole A : A member of the class of pyrroles that is 1'H-1,3'-bipyrrole substituted by four chloro groups at positions 4, 4', 5 and 5' and two 2-hydroxybenzoyl moieties at positions 2 and 2'. It is isolated from Streptomyces sp.CNQ-418 and exhibits cytotoxic and antibacterial activities. marinopyrrole A: antibiotic from a marine Streptomyces sp.; structure in first source | aromatic ketone; organochlorine compound; phenols; pyrroles | antibacterial agent; antimicrobial agent; antineoplastic agent; bacterial metabolite; marine metabolite |
navitoclax | aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound | antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor | |
meiogynin a | meiogynin A: from the bark of Meiogyne cylindrocarpa; structure in first source | ||
1, 3-di-(n-carboxybenzoyl-leucyl-leucyl)amino acetone | 1, 3-di-(N-carboxybenzoyl-leucyl-leucyl)amino acetone: structure in first source | ||
pf 3084014 | nirogacestat : A member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment. nirogacestat: an antineoplastic agent | ||
bms 708163 | BMS 708163: structure in first source | oxadiazole; ring assembly | |
ro 4929097 | dibenzoazepine; dicarboxylic acid diamide; lactam; organofluorine compound | EC 3.4.23.46 (memapsin 2) inhibitor | |
jnj 40418677 | |||
(r)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1h-pyrazolo(4,3-c)quinoline | (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo(4,3-c)quinoline: gamma secretase inhibitor; structure in first source | ||
jy-1-106 | JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source | ||
kf38789 | KF38789: a non-carbohydrate low MW cpd that Inhibits P-selectin specific cell adhesion; structure in first source |